SGLT 2 Inhibitors: Mechanisms, Clinical Applications, and Future Directions
DOI:
https://doi.org/10.22399/ijcesen.615Keywords:
SGLT2 Inhibitors, Diabetes Mellitus, Cardiovascular DiseaseAbstract
Due to the progressive and painful nature of type 2 diabetes (T2D), treatment may require periodic evaluation of patients, intensifying glucose-lowering therapy when glycaemic targets are not achieved and testing new methods. Among the newer classes of glucose-lowering drugs, sodium-glucose cotransporter 2 inhibitors (SGLT2is), which increase urinary glucose excretion to reduce hyperglycaemia, have made an impressive entry into the T2D treatment arsenal. Given their unique insulin-independent mode of action and favourable efficacy-adverse effect profiles, and their apparent benefits on cardiovascular-renal outcomes in intermediate-high-risk T2D patients, which have led to the updating of guidelines and product monographs, the role of this drug class in multidrug regimens is promising. However, despite much speculation based on pharmacokinetic and pharmacodynamic properties, physiological rationale and potential synergism, the glycaemic and pleiotropic effects of these agents when combined with other classes of glucose-lowering drugs remain largely under-researched. Therefore, this review discusses the mechanisms, clinical applications and future therapeutic role of SGLT2 inhibitors with a review of the literature.
References
Fonseca-Correa, J. I. & Correa-Rotter, R. (2021). Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Frontiers in Medicine. 20(8);777861. doi: 10.3389/fmed.2021.777861. DOI: https://doi.org/10.3389/fmed.2021.777861
Scheen, A. J. (2020). Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature reviews endocrinology. 16(10);556-577. doi: 10.1038/s41574-020-0392-2. DOI: https://doi.org/10.1038/s41574-020-0392-2
Sen, T. & Heerspink, H. J. L. (2021). A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell metabolism. 33(4); 732-739 https://doi.org/10.1016/j.cmet.2021.02.016 DOI: https://doi.org/10.1016/j.cmet.2021.02.016
Zhang, C., Gu, L., Xie, H., Liu, Y., Huang, P., Zhang, J., ... & Zhang, J. (2023). Glucose transport, transporters and metabolism in diabetic retinopathy. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 62(52);166995. https://doi.org/10.1002/anie.202314303 DOI: https://doi.org/10.1016/j.bbadis.2023.166995
Batchuluun, B., Pinkosky, S. L., & Steinberg, G. R. (2022). Lipogenesis inhibitors: therapeutic opportunities and challenges. Nature Reviews Drug Discovery, 21(4), 283-305. DOI: https://doi.org/10.1038/s41573-021-00367-2
Pantiora, P., Furlan, V., Matiadis, D., Mavroidi, B., Perperopoulou, F., Papageorgiou, A. C., ... & Labrou, N. E. (2022). Monocarbonyl curcumin analogues as potent inhibitors against human glutathione transferase p1-1. Antioxidants, 12(1), 63. DOI: https://doi.org/10.3390/antiox12010063
Feder, D., de Fatima Veiga Gouveia, M. R., Govato, T. C. P., & Nassis, C. D. Z. (2020). SGLT2 inhibitors and the mechanisms involved in weight loss. Current Pharmacology Reports, 6;346-353. DOI: https://doi.org/10.1007/s40495-020-00236-3
Janež, A. & Fioretto, P. (2021). SGLT2 inhibitors and the clinical implications of associated weight loss in type 2 diabetes: a narrative review. Diabetes Therapy. 12(8);2249-2261. doi: 10.1007/s13300-021-01104-z DOI: https://doi.org/10.1007/s13300-021-01104-z
Cheong, A. J. Y., Teo, Y. N., Teo, Y. H., Syn, N. L., Ong, H. T., Ting, A. Z., ... & Sia, C. H. (2022). SGLT inhibitors on weight and body mass: a meta‐analysis of 116 randomized‐controlled trials. Obesity, 30(1);117-128. DOI: https://doi.org/10.1002/oby.23331
Mohajan, D., & Mohajan, H. K. (2024). Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Antidiabetics Medications for Treating Diabetes. Innovation in Science and Technology, 3(4);103-108. DOI: https://doi.org/10.56397/IST.2024.07.10
Palmer, B. F., & Clegg, D. J. (2023). Kidney-protective effects of SGLT2 inhibitors. Clinical Journal of the American Society of Nephrology, 18(2);279-289. DOI: https://doi.org/10.2215/CJN.09380822
Vallon, V. & Verma, S. (2021). Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol.10(83);503-528. doi: 10.1146/annurev-physiol-031620-095920. DOI: https://doi.org/10.1146/annurev-physiol-031620-095920
Bailey, C. J., Day, C., & Bellary, S. (2022). Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 22(1);39-52. doi: 10.1007/s11892-021-01442-z. DOI: https://doi.org/10.1007/s11892-021-01442-z
Ravindran, S. & Munusamy, S. (2022). Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. Journal of cellular physiology. 237(2);1182-1205. doi: 10.1002/jcp.30621. DOI: https://doi.org/10.1002/jcp.30621
Suijk, D. L., van Baar, M. J., van Bommel, E. J., Iqbal, Z., Krebber, M. M., Vallon, V., ... & van Raalte, D. H. (2022). SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clinical Journal of the American Society of Nephrology, 17(5), 663-671. DOI: https://doi.org/10.2215/CJN.11480821
Gronda, E., Jessup, M., Iacoviello, M., Palazzuoli, A., & Napoli, C. (2020). Glucose metabolism in the kidney: neurohormonal activation and heart failure development. Journal of the American Heart Association, 9(23), e018889. DOI: https://doi.org/10.1161/JAHA.120.018889
Sędzikowska, A. & Szablewski, L. (2021). Human glucose transporters in renal glucose homeostasis. Int J Mol Sci. 22(24);13522. doi: 10.3390/ijms222413522 DOI: https://doi.org/10.3390/ijms222413522
Vallon, V. & Nakagawa, T. (2021). Renal tubular handling of glucose and fructose in health and disease. Compr Physiol. 12(1);2995-3044. doi: 10.1002/cphy.c210030. DOI: https://doi.org/10.1002/cphy.c210030
Vallon, V. (2024). State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications. Am J Hypertens. 37(11):841-852. doi: 10.1093/ajh/hpae092. DOI: https://doi.org/10.1093/ajh/hpae092
Marton, A., Kaneko, T., Kovalik, J. P., Yasui, A., Nishiyama, A., Kitada, K., & Titze, J. (2021). Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nature Reviews Nephrology, 17(1);65-77. DOI: https://doi.org/10.1038/s41581-020-00350-x
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., ... & Sasso, F. C. (2022). An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. International Journal of Molecular Sciences, 23(7);3651. DOI: https://doi.org/10.3390/ijms23073651
Unno, K., Taguchi, K., Takagi, Y., Hase, T., Meguro, S., & Nakamura, Y. (2023). Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption. International Journal of Molecular Sciences, 24(7), 6278. DOI: https://doi.org/10.3390/ijms24076278
Ping, X., Wang, G., & Gao, D. (2024). … Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption. J Clin Pharmacol 64(6);672-684. doi: 10.1002/jcph.2413 DOI: https://doi.org/10.1002/jcph.2413
Shirakawa, K. & Sano, M. (2020). Sodium-glucose co-transporter 2 inhibitors correct metabolic maladaptation of proximal tubular epithelial cells in high-glucose conditions. International journal of molecular sciences. Int J Mol Sci. 21(20);7676. doi: 10.3390/ijms21207676. DOI: https://doi.org/10.3390/ijms21207676
Layton, A. T. & Vallon, V. (2023). Did you know how SGLT2 inhibitors protect the kidney?. Acta Physiologica. 238(4);e14011 https://doi.org/10.1111/apha.14011 DOI: https://doi.org/10.1111/apha.14011
Benedetti, R., Benincasa, G., Glass, K., Chianese, U., Vietri, M. T., Congi, R., ... & Napoli, C. (2022). Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacological Research, 175;106039. DOI: https://doi.org/10.1016/j.phrs.2021.106039
Baghel, R., Chhikara, N., Kumar, P., & Tamrakar, A. K. (2024). SGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23). Expert Opinion on Therapeutic Patents, 34(9);807-823. DOI: https://doi.org/10.1080/13543776.2024.2379929
Evans, M., Morgan, A. R., Whyte, M. B., Hanif, W., Bain, S. C., Kalra, P. A., ... & Strain, W. D. (2022). New Therapeutic Horizons in Chronic Kidney Disease: The role of SGLT2 inhibitors in clinical practice. Drugs, 82(2);97-108. DOI: https://doi.org/10.1007/s40265-021-01655-2
Karunarathna, I., & Jayathilaka, P. (2024). Comprehensive Management of Type 2 Diabetes Mellitus: From Prevention to Novel Therapeutic Approaches. Uva Clinical Lab. Retrieved from Comprehensive Management of Type, 2.
Dave, C. V., Schneeweiss, S., Wexler, D. J., Brill, G., & Patorno, E. (2020). Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018. Diabetes care, 43(4), 921-924. DOI: https://doi.org/10.2337/dc19-1943
González-González, J. G., González-Colmenero, A. D., Millán-Alanís, J. M., Lytvyn, L., Solis, R. C., Mustafa, R. A., ... & Rodríguez-Gutiérrez, R. (2021). Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review. BMJ open, 11(7), e049130. DOI: https://doi.org/10.1136/bmjopen-2021-049130
Qaseem, A., Obley, A. J., Shamliyan, T., Hicks, L. A., Harrod, C. S., Crandall, C. J., & Clinical Guidelines Committee of the American College of Physicians. (2024). Newer pharmacologic treatments in adults with type 2 diabetes: A clinical guideline from the American College of Physicians. Annals of Internal Medicine, 177(5), 658-666. DOI: https://doi.org/10.7326/M23-2788
Agarwal, A., Zeng, X., Li, S., Rayner, D., Foroutan, F., Aertgeerts, B., ... & Agoritsas, T. (2024). Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline. BMJ 387;e080257. doi: 10.1136/bmj-2024-080257 DOI: https://doi.org/10.1136/bmj-2024-080257
Hojná, S., Malínská, H., Hüttl, M., Vaňourková, Z., Marková, I., Miklánková, D., ... & Vaněčková, I. (2024). Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet. Biomedicine & Pharmacotherapy, 174;116520. DOI: https://doi.org/10.1016/j.biopha.2024.116520
Scheen, A. J., & Delanaye, P. (2022). Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Review of Endocrinology & Metabolism, 17(1), 35-46. DOI: https://doi.org/10.1080/17446651.2022.2014322
Sardu, C., Trotta, M. C., Sasso, F. C., Sacra, C., Carpinella, G., Mauro, C., ... & Marfella, R. (2023). SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. Cardiovascular Diabetology, 22(1);80. DOI: https://doi.org/10.1186/s12933-023-01814-7
Cai, D., Chen, Q., Mao, L., Xiao, T., Wang, Y., Gu, Q., ... & Sun, L. (2024). Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients. European Journal of Clinical Pharmacology, 80(4);613-620. DOI: https://doi.org/10.1007/s00228-024-03623-7
Margonato, D., Galati, G., Mazzetti, S., Cannistraci, R., Perseghin, G., Margonato, A., & Mortara, A. (2021). Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. Heart failure reviews, 26;337-345. DOI: https://doi.org/10.1007/s10741-020-10024-2
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2022). Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovascular Research, 118(10);2231-2252. DOI: https://doi.org/10.1093/cvr/cvab271
Liu, H., Sridhar, V. S., Boulet, J., Dharia, A., Khan, A., Lawler, P. R., & Cherney, D. Z. (2022). Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism, 126;154918. DOI: https://doi.org/10.1016/j.metabol.2021.154918
Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., ... & Solomon, S. D. (2022). SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet, 400(10354);757-767. DOI: https://doi.org/10.1016/S0140-6736(22)01429-5
Van der Aart-van der Beek, A. B., de Boer, R. A., & Heerspink, H. J. (2022). Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nature Reviews Nephrology, 18(5);294-306. DOI: https://doi.org/10.1038/s41581-022-00535-6
Bartolo, C., Hall, V., Friedman, N. D., Lanyon, C., Fuller, A., Morrissey, C. O., & Athan, E. (2021). Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports. BMC Infectious Diseases, 21;1-4. DOI: https://doi.org/10.1186/s12879-021-05982-3
Delanaye, P. & Scheen, A. J. (2021). The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection. Diabetes & metabolism. 47(6);101285. doi: 10.1016/j.diabet.2021.101285 DOI: https://doi.org/10.1016/j.diabet.2021.101285
Ehrmann, D., Kulzer, B., Roos, T., Haak, T., Al-Khatib, M., & Hermanns, N. (2020). Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes. The Lancet Diabetes & Endocrinology, 8(5);436-446. DOI: https://doi.org/10.1016/S2213-8587(20)30042-5
Hare, M. J., Deitch, J. M., Kang, M. J., & Bach, L. A. (2021). Clinical, psychological and demographic factors in a contemporary adult cohort with diabetic ketoacidosis and type 1 diabetes. Internal medicine journal, 51(8);1292-1297. DOI: https://doi.org/10.1111/imj.14877
Say, A., Ayar, A., & Çakir, D. (2017). Interaction between grapefruit juice and drugs. Acta Physica Polonica A, 132(3);1030-1031. DOI: https://doi.org/10.12693/APhysPolA.132.1030
Helvaci, B. C., Erdogan, B. T., Ozdemir, D., Topaloglu, O., & Cakir, B. (2024). Euglycemic diabetic ketoacidosis in a patient with new-onset type 1 diabetes following a ketogenic diet: a potential risk of a dangerous dietary trend. Archives of endocrinology and metabolism, 68;e230229. DOI: https://doi.org/10.20945/2359-4292-2023-0229
Algaly, G., Abdelrahman, A., & Ahmed, S. M. (2023). Euglycemic diabetic ketoacidosis in a pregnant woman. Journal of the American College of Emergency Physicians Open, 4(6);e13089. DOI: https://doi.org/10.1002/emp2.13089
Mende, C. W. (2022). Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape. Advances in therapy. 39(1);148-164. doi: 10.1007/s12325-021-01994-2 DOI: https://doi.org/10.1007/s12325-021-01994-2
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., ... & Xu, S. (2021). Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics, 11(9);4502 -4515. doi: 10.7150/thno.54498. DOI: https://doi.org/10.7150/thno.54498
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Computational and Experimental Science and Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
